ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth

Key Takeaways ACAD posted Q4 EPS of 16 cents, topping estimates, as revenues rose 9% to $284M.Nuplazid sales rose 7% to $174.4M, while Daybue climbed 13% to $109.6M.ACAD guides 2026 revenues of $1.22-$1.28B; EU review of trofinetide faces likely CHMP rejection.Acadia Pharmaceuticals (ACAD) reported fourth-quarter 2025 earnings per share (EPS) of 16 cents (excluding tax benefit), which beat the Zacks Consensus Estimate of 12 cents. In the year-ago quarter, the company had reported adjusted EPS of 17 cents.In ...